GTN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Installed-Base RevenueRevenue is diversified across capital equipment, service contracts, and consumables, while the installed base supports repeat demand over long equipment lifecycles. This mix can make customer relationships more durable and reduce reliance on any single purchase cycle.
Profitability RecoveryImproving net income and healthy operating profitability indicate that Getinge is converting its business activity into stronger earnings than in the recent comparison periods. If sustained, this recovery can support investment, service capability, and internally funded growth.
Improving Cash GenerationStronger operating and free cash flow, together with substantial free-cash-flow conversion of net income, supports the quality of reported earnings. Better cash generation should improve Getinge’s ability to fund operations and meet obligations without relying solely on external financing.
Bears Say
Flat Revenue TrendLimited revenue growth suggests that the recent earnings recovery is not yet being driven by broad top-line expansion. Without stronger demand or market share gains, Getinge may have less operating leverage and fewer opportunities to compound earnings over the next several quarters.
Margins Below Prior PeaksAlthough current profitability is healthy, margins below earlier peak levels show that the recovery remains incomplete. Persistent underperformance versus those periods could constrain cash generation, investment capacity, and the company’s ability to absorb cost pressure while maintaining returns.
Rising Debt And Limited FlexibilityHigher debt alongside only moderate cash flow coverage reduces financial flexibility if operating conditions weaken. It may leave less capacity for aggressive deleveraging, acquisitions, or increased shareholder returns unless the recent improvement in profitability and cash generation persists.
Getinge News
GTN FAQ
What was Getinge’s price range in the past 12 months?
Currently, no data Available
What is Getinge’s market cap?
Getinge’s market cap is CHF5.89B.
When is Getinge’s upcoming earnings report date?
Getinge’s upcoming earnings report date is Jan 26, 2027 which is in 94 days.
How were Getinge’s earnings last quarter?
Getinge released its earnings results on Oct 21, 2026. The company reported CHF0.258 earnings per share for the quarter, beating the consensus estimate of CHF0.214 by CHF0.045.
Is Getinge overvalued?
According to Wall Street analysts Getinge’s price is currently Undervalued.
Does Getinge pay dividends?
Getinge does not currently pay dividends.
What is Getinge’s EPS estimate?
Getinge’s EPS estimate is 0.41.
How many shares outstanding does Getinge have?
Getinge has 254,152,370 shares outstanding.
What happened to Getinge’s price movement after its last earnings report?
Getinge reported an EPS of CHF0.258 in its last earnings report, beating expectations of CHF0.214. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Getinge?
Currently, no hedge funds are holding shares in CH:GTN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Getinge
Getinge AB, founded in 1904 and headquartered in Gothenburg, Sweden, is a prominent global supplier of medical technology solutions. The company's extensive portfolio is designed for critical healthcare environments, including operating rooms, intensive care units, and sterile processing facilities. Its operations are divided into three core segments: Acute Care Therapies, Life Science, and Surgical Workflows. Getinge offers a comprehensive array of specialized equipment and systems. This encompasses advanced solutions for sterile processing and containment, such as sterilizers, washers, isolators, and automated logistic systems. For the life sciences sector, they provide bioreactors, bioprocess control systems, and associated analytics tools. Within acute care and surgical settings, their offerings range from anesthesia machines, specialized monitoring systems, and various disposables, to instruments for cardiac surgery (like beating heart stabilizers), mechanical ventilation products, and extracorporeal life support (ECMO) solutions. Additionally, Getinge provides infrastructure for operating rooms, including lighting, tables, modular systems, and integrated management tools, alongside products for cleaning, disinfection, packaging, and comprehensive sterile supply management. Their product line further extends to diverse catheters (thoracic, endovascular), endoscopic vessel harvesting systems, patient flow and transport solutions, and specialized devices for vascular and cardiothoracic surgery. The company distributes its broad range of products globally through its proprietary sales companies, as well as via agents and distributors, serving markets across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region.
GTN Stock 12 Month Forecast
Average Price Target
CHF19.40
BONESUPPORT HOLDING AB
―
Xvivo Perfusion AB
―
Bactiguard Holding AB
―
Sectra AB Class B
―
Sedana Medical AB
―